1762 — Chunghwa Chemical Synthesis & Biotech Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Market Cap
TWD2.22bn
Enterprise Value
TWD2.86bn
Revenue
TWD1.35bn

Annual income statement for Chunghwa Chemical Synthesis & Biotech Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,544	1,935	2,117	2,086	1,347
Cost of Revenue
Gross Profit	687	949	962	757	394
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	1,275	1,496	1,654	1,806	1,341
Operating Profit	269	438	464	281	6.34
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	650	498	583	333	57.2
Provision for Income Taxes
Net Income After Taxes	532	401	466	265	53
Minority Interest
Net Income Before Extraordinary Items
Net Income	532	401	466	265	53
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	532	401	466	265	53
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.17	5.12	5.94	3.39	0.932
Dividends per Share